Theravance Biopharma, Inc. Operating Lease Liability
Theravance Biopharma, Inc. (TBPH) had Operating Lease Liability of $42.70 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-23
- 2025-12-31: Operating Lease, Liability $42.70M.
- 2024-12-31: Operating Lease, Liability $49.82M.
- 2023-12-31: Operating Lease, Liability $49.16M.
- 2022-12-31: Operating Lease, Liability $52.16M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $42.70M 10-K · filed 2026-03-23 |
| 2024-12-31 | $49.82M 10-K · filed 2026-03-23 |
| 2023-12-31 | $49.16M 10-K · filed 2025-03-07 |
| 2022-12-31 | $52.16M 10-K · filed 2024-03-01 |
| 2021-12-31 | $53.18M 10-K · filed 2023-03-01 |
| 2020-12-31 | $57.09M 10-K · filed 2022-02-28 |
| 2019-12-31 | $55.49M 10-K · filed 2021-02-26 |
| 2019-09-30 | $55.45M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $56.45M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $56.91M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |